PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16174656-4	2006	Compared with placebo, trimetazidine induced 1) an increase in insulin-induced forearm glucose uptake and glucose oxidation accompanied by a reduction in forearm lipid oxidation and citrate release and 2) a decrease of endothelin-1 release paralleled by a significant increase in forearm cGMP release.	Trimetazidine	23-36	insulin	Homo sapiens	63-70	
16503536-1	2006	OBJECTIVE: To evaluate the efficacy of trimetazidine on insulin resistance in patients with coronary heart disease (CHD).	Trimetazidine	39-52	insulin	Homo sapiens	56-63	
16503536-5	2006	After 8 weeks" trimetazidine therapy, the fasting insulin and that at 2 h after oral glucose were decreased (P<0.01), and the insulin sensitivity index was improved (P<0.01).	Trimetazidine	15-28	insulin	Homo sapiens	50-57	
16503536-5	2006	After 8 weeks" trimetazidine therapy, the fasting insulin and that at 2 h after oral glucose were decreased (P<0.01), and the insulin sensitivity index was improved (P<0.01).	Trimetazidine	15-28	insulin	Homo sapiens	129-136	
16503536-6	2006	CONCLUSION: Trimetazidine may produce obvious therapeutic effect on insulin resistance in CHD patients.	Trimetazidine	12-25	insulin	Homo sapiens	68-75	
18765391-10	2008	Trimetazidine decreased insulin resistance (glucose: 5.9+/-0.7 versus 5.5+/-0.6 mmol/L, P=0.047; insulin: 10+/-6.9 versus 7.6+/-3.6 mU/L, P=0.031; homeostasis model assessment index: 2.75+/-2.28 versus 1.89+/-1.06, P=0.027).	Trimetazidine	0-13	insulin	Homo sapiens	24-31	
18765391-10	2008	Trimetazidine decreased insulin resistance (glucose: 5.9+/-0.7 versus 5.5+/-0.6 mmol/L, P=0.047; insulin: 10+/-6.9 versus 7.6+/-3.6 mU/L, P=0.031; homeostasis model assessment index: 2.75+/-2.28 versus 1.89+/-1.06, P=0.027).	Trimetazidine	0-13	insulin	Homo sapiens	97-104	
18765391-15	2008	Trimetazidine improved whole-body insulin sensitivity and glucose control in these insulin-resistant idiopathic dilated cardiomyopathy patients, thus hypothetically countering the myocardial damage of insulin resistance.	Trimetazidine	0-13	insulin	Homo sapiens	34-41	
18765391-15	2008	Trimetazidine improved whole-body insulin sensitivity and glucose control in these insulin-resistant idiopathic dilated cardiomyopathy patients, thus hypothetically countering the myocardial damage of insulin resistance.	Trimetazidine	0-13	insulin	Homo sapiens	83-90	
16174656-6	2006	In conclusion, for the first time, we demonstrated that insulin-induced forearm glucose oxidation and forearm cGMP release were increased whereas forearm endothelin-1 release was decreased during trimetazidine treatment.	Trimetazidine	196-209	insulin	Homo sapiens	56-63	
35365489-0	2022	Trimetazidine and exercise offer analogous improvements to the skeletal muscle insulin resistance of mice through Nrf2 signaling.	Trimetazidine	0-13	insulin	Homo sapiens	79-86	
35365489-8	2022	RESULTS: In vivo, TMZ and exercise decreased the blood glucose and insulin levels and homeostasis model assessment of IR index, increased skeletal muscle insulin signaling-related protein ratios of p-IRS1/IRS1 and p-AKT/AKT, and both interventions activated Nrf2 signaling and reduced oxidative stress production in HFD mice.	Trimetazidine	18-21	insulin	Homo sapiens	67-74	
35365489-8	2022	RESULTS: In vivo, TMZ and exercise decreased the blood glucose and insulin levels and homeostasis model assessment of IR index, increased skeletal muscle insulin signaling-related protein ratios of p-IRS1/IRS1 and p-AKT/AKT, and both interventions activated Nrf2 signaling and reduced oxidative stress production in HFD mice.	Trimetazidine	18-21	insulin	Homo sapiens	154-161	
35365489-9	2022	In vitro, TMZ reduced the oxidative stress reaction, increased the ratios of p-AKT/AKT and p-IRS1/IRS1, and attenuated the insulin stimulation of PA-induced glucose uptake.	Trimetazidine	10-13	insulin	Homo sapiens	123-130